Green leaf pharmaceutical injection with rothegotin retardation microsphere (LY03003) launches Phase III clinical trial in China

June 20, Green leafPharmaceutical(a notice) announced that the injection of rothegotin reprieve microsphere (LY03003) in China to launch phase III clinicaltrial()about LY 03003
LY 03003 is the key central nervous system development of green leaf pharmaceutical long-term reprieve preparation platform in the research andproduct(one, currently in China, the United States, Europe and Japan market for simultaneous development, in China and the United States respectively completed Phase I clinical trials and exempted Phase II clinical trials, Green leaf pharmaceutical spouts already have patents(patents in China, the United States, Japan, Europe and South Korea) covering LY 03003 formulations, compoundssynthetic(methods and impurities-related(the above- The patent for the preparation will remain in effect until 2031 (or specifically 2032 in the United States)Greenleaf Pharmaceuticals plans to register and list LY 03003 in China, the United States, Japan, Europe and other countriesUSING A WEEKLY INTRAMUSCULAR INJECTION, LY 03003 IS THE WORLD'S FIRST LONG-TERM PRODUCTION OF CO
NTINUOUS DOPAMINE STIMULATIONThe stable release of LY 03003 in the human body can reduce the drug in Parkinson's patients (the treatment of the "switch" effect that is prone to appear, significantly improve the risk of motor complications in patients with advanced Parkinson's disease, and long-term application is expected to delay the development of motor complications.) At the same time, Green leaf pharmaceuticals are further developing a january-time injection with rothegotin reprieve microspheres